Today's pharmaceutical business stocks have changed, and a large number of pharmaceutical companies such as Yifeng Pharmacy, Yixintang, and Jianzhijia have risen to the limit

【Pharmaceutical Network Pharmaceutical Stock Market】 News on December 29, pharmaceutical stocks rose across the board, pharmaceutical business direction led the rise, Yifeng Pharmacy, Yixintang, Jianzhijia, Lukang Pharmaceutical, Weixinkang, Weiguang Biotechnology and other stocks rose to the limit
.
Yifeng Pharmacy At 10:32 on December 29, Yifeng Pharmacy rose intraday to 63.
97 yuan, and the current closed order is 21574 lots, equivalent to 138 million yuan
.
Up to now, the transaction has reached 253 million yuan, with a turnover rate of 0.
57%.

According to the data, Yifeng Pharmacy's main business is the chain retail business
of medicines, health products, health foods, medical devices, personal care products and health-related daily convenience products.
In recent years, the company has continued to promote the construction of an ecological pharmaceutical new retail system based on membership, big data, Internet medical treatment, health management, etc.
, actively promoted chronic disease management, online diagnosis and treatment, and combined online and offline health housekeeper and family doctor services, and is committed to member-centered omni-channel, full-scenario, and full-life cycle health management
.
Yixintang At 10:29 on December 29, Yixintang rose intraday to 33.
18 yuan, and the current closed order is 103474, equivalent to 343 million yuan
.
Up to now, the transaction has reached 215 million yuan, with a turnover rate of 1.
69%.

According to the data, Yixintang's main business is pharmaceutical retail chain and pharmaceutical wholesale business
.
The company's main products are Chinese and Western patent medicines, medical devices and family planning, disinfection products, and traditional Chinese medicine
.
The company is an enterprise with strong comprehensive strength of domestic chain pharmacies, and has a large-scale pharmaceutical direct chain network
in southwest China (centered on Yunnan, radiating Sichuan, Qian, Yugui, Jin, etc.
).
Data show that in the first three quarters of 2022, the company's main revenue was 12.
025 billion yuan, a year-on-year increase of 14.
55%; The net profit attributable to the parent was 677 million yuan, down 11.
33% from the same period last year Jianzhijia At 9:57 on December 29, Jianzhijia rose intraday to 80.
77 yuan, and the current closed order is 14401 lots, equivalent to 116 million yuan
.
Up to now, the transaction has been 97.
498 million yuan, with a turnover rate of 2.
14%.

According to the data, Jianzhijia is mainly engaged in the chain retail business of health products such as medicines, health foods, personal care products, family health products, convenience foods, daily consumables, etc.
, and provides related professional services
.
The company's main products are Chinese and Western medicines, Chinese medicinal materials, health foods, personal care products, etc
.
The company carries out a variety of e-commerce businesses of "online order store pick-up, online order store delivery" and entrusted third-party logistics distribution, mainly in the following three ways: first, self-owned e-commerce platform sales, including PC platform (Jianzhijia online pharmacy), mobile shopping platform (Jianzhijia APP), WeChat platform (Jianzhijia public account) and Jiaegou electronic shelves to carry out sales; The second is to carry out e-commerce business through third-party network platforms such as Tmall, Jingdong Mall, Suning.
com, Pinduoduo and other channels; The third is to explore a new model
of fast and convenient store sales through cooperation with platforms such as "Meituan Takeaway" and "Ele.
me".
Lukang Medicine At 10:11 on December 29, Lukang Medicine touched the price limit
.
The current price is 7.
13, up 10.
03%.

According to the data, Lukang Pharmaceutical is an antibiotic enterprise, and its main business is the research and development, production and sales
of pharmaceutical products.
The company's products involve antibiotics, amino acids, cardiovascular and cerebrovascular, semi-synthetic antibiotic APIs, biological drugs and related preparations, infusions, proprietary Chinese medicines, pharmaceutical intermediates, antibiotics for animal health, starch, glucose, etc
.
The company announced on December 28 that in order to further optimize the company's management structure, improve operational efficiency and reduce management costs, it agreed to absorb and merge Shandong Lukang Biological Manufacturing Co.
, Ltd.
, a wholly-owned subsidiary of the company, Shandong Lukang Biological Manufacturing Co.
, Ltd
.
In addition, on the 28th, the company was financed to buy 8.
0842 million yuan, and the current financing balance is 291 million yuan
.
Wei Xinkang At 10:33 on December 29, Weixin Kang rose intraday to 15.
61 yuan, and the current order is 49,359 lots, equivalent to 77.
0494 million yuan
.
Up to now, the transaction has been 63.
3426 million yuan, with a turnover rate of 0.
99%.

According to the data, the main business of Weixin Kang is the research and development, production and sales of chemical preparations and their APIs, and the production and sales of liver-protecting drugs and antibiotic products
.
The company's leading products include multivitamin for injection (12), a variety of trace element injection, pediatric multivitamin injection (13), compound electrolyte injection (V), acetylcysteine solution for inhalation, potassium aspartate injection, potassium magnesium aspartate for injection
.
It is reported that the company and its wholly-owned subsidiaries Inner Mongolia Baiyi Pharmaceutical Co.
, Ltd.
and Beijing Jingwei Xinkang Pharmaceutical Technology Development Co.
, Ltd.
received the "Drug Registration Approval" and "New Drug Certificate" for pediatric multivitamins for injection (13) approved and issued by the State Food and Drug Administration
.
Weiguang Biology At 9:37 on December 29, Weiguang Biotech rose to 31.
28 yuan, and the current order is 57999 lots, equivalent to 181 million yuan
.
Up to now, the transaction has been 38.
5999 million yuan, with a turnover rate of 0.
56%.

According to the data, Weiguang Biotechnology is an enterprise
engaged in the production, sales and research and development of biological products.
The company now mainly focuses on the production and operation of blood products and drug research and development
.
The company's main products are human blood albumin, intravenous human immunoglobulin, hepatitis B human immunoglobulin, rabies patient immunoglobulin, tetanus human immunoglobulin, etc
.
In terms of R&D projects, the lyophilized human rabies vaccine project has conducted a preclinical communication meeting of the drug review center, the human fibrinogen project has obtained marketing authorization, the human prothrombin complex project has completed III.
clinical research, and the human coagulation factor VIII project has started III.
clinical trials
.
In addition, on December 29, Sunward Pharmaceutical, Wellcome Pharmaceutical rose by more than 12%, and Laomin, Da Shenlin, Fangsheng Pharmaceutical, Enhua Pharmaceutical, etc.
rose by more than 7%.

The agency said that after the gradual easing of the epidemic, China's chain pharmacy leaders are expected to achieve high revenue growth with the further recovery of drug demand and customer flow
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.